The client, a large pharmaceutical company, wanted to understand the implications of the Office of Fair Trading decision in respect of hospital vs. community pricing of Morphine Continus® in the UK for its own pricing strategies.
Translucency reviewing the case and, using its detailed existing knowledge of pharmaceutical pricing in the UK, and incorporating information our client had given about its own current approach to pricing, prepared a full briefing about the issues.
Translucency’s report related the findings to the likely effects on the client’s approach to pricing in the UK.
The client recommendations have informed the client’s decisions on relative pricing of products in the hospital and in the community.